Welcome to our dedicated page for TransMedics Group news (Ticker: TMDX), a resource for investors and traders seeking the latest updates and insights on TransMedics Group stock.
TransMedics Group, Inc. reports developments in medical technology for organ transplant therapy, centered on its Organ Care System, or OCS, for preserving and monitoring donor lungs, hearts and livers outside the body. Company updates commonly cover OCS utilization through the National OCS Program, transplant logistics services, aviation fleet capacity, revenue trends and margin drivers.
Recurring news also includes clinical and regulatory disclosures tied to OCS programs and the Controlled Hypothermic Organ Preservation System, tax-accounting updates, material agreements, governance actions and employee equity awards. These developments reflect the company's commercial-stage model in organ preservation, transplant logistics and transplant-service support.
TransMedics (NASDAQ: TMDX), a medical technology company focused on organ transplant therapy, has granted equity incentives to 14 new employees as employment inducements. The compensation package includes 21,458 non-qualified stock options with an exercise price of $105.24 per share and 14,283 restricted stock units (RSUs).
The stock options will vest 25% after one year, with the remaining vesting monthly over three years. The RSUs will vest 25% annually over four years. Both grants require continued employment and were approved under Nasdaq Listing Rule 5635(c)(4) through the TransMedics Group, Inc. Inducement Plan.
TransMedics (NASDAQ: TMDX), a medical technology company specializing in organ transplant therapy, reported strong Q2 2025 financial results. The company achieved revenue of $157.4 million, marking a 38% increase year-over-year, and generated net income of $34.9 million ($0.92 per diluted share).
Key highlights include receiving conditional IDE approval for the Next-Gen OCS™ Lung trial, launching the NOP ACCESS™ digital ecosystem, and maintaining a strong 61% gross margin. The company has raised its full-year 2025 revenue guidance to $585-605 million, representing 35% growth at the midpoint compared to the previous guidance of $565-585 million.
TransMedics maintains a robust financial position with $400.6 million in cash as of June 30, 2025, and remains focused on achieving its target of 10,000 US NOP transplants by 2028.
TransMedics (NASDAQ: TMDX), a medical technology company specializing in organ transplant therapy solutions, announced its participation in the Canaccord Genuity 45th Annual Growth Conference. The company's management team will deliver a presentation on Tuesday, August 12, 2025, at 11:30 a.m. ET at the InterContinental Boston Hotel.
Investors can access both the live and archived webcast of the fireside chat, along with the company's standard investor presentation, through the "Investors" section of TransMedics' website at investors.transmedics.com.
TransMedics (NASDAQ: TMDX), a medical technology company focused on organ transplant therapy, has scheduled its Second Quarter 2025 financial results announcement for July 30, 2025, after market close.
The company will host a conference call at 4:30 p.m. ET / 1:30 p.m. PT to discuss the results. Investors can join via phone using specific dial-in numbers or access the webcast through TransMedics' investor relations website.
TransMedics (Nasdaq: TMDX), a medical technology company focused on organ transplant therapy, has announced its participation in two major investor conferences in June 2025. The company will present at the William Blair 45th Annual Growth Stock Conference in Chicago on June 3 at 5:00 p.m. EST and participate in a fireside chat at the Goldman Sachs 46th Annual Global Healthcare Conference in Miami on June 9 at 8:00 a.m. EST. Both presentations will be available via webcast on TransMedics' investor relations website.
TransMedics Group (Nasdaq: TMDX), a medical technology company focused on organ transplant therapy, has scheduled its first quarter 2025 financial results announcement for May 8, 2025, after market close.
The company will host a conference call at 4:30 p.m. ET / 1:30 p.m. PT on the same day. Investors can participate by dialing (844) 676-6010 (domestic) or (412) 634-6944 (international). A live and archived webcast will be available on the company's investor relations website.
TransMedics Group (TMDX) announced the granting of inducement awards to three new employees on March 28, 2025. The compensation package includes:
- 1,570 non-qualified stock options with an exercise price of $68.58 per share
- 1,043 restricted stock units (RSUs)
The stock options will vest 25% after one year, with the remaining vesting monthly over three years. The RSUs will vest 25% annually over four years. Both grants require continued employment and were approved by the Compensation Committee under Nasdaq Listing Rule 5635(c)(4) through the TransMedics Inducement Plan.
TransMedics (TMDX) reported strong financial results for Q4 and full year 2024. The company achieved total revenue of $121.6 million in Q4 2024, up 50% year-over-year, and full-year revenue of $441.5 million, representing an 83% increase from 2023.
Key highlights include net income of $6.9 million ($0.19 per diluted share) in Q4 and $35.5 million ($1.01 per diluted share) for the full year 2024. The company completed 3,715 U.S. OCS cases in 2024, a 58% increase from 2023, and achieved a 20.9% overall OCS market share across all organs.
For 2025, TransMedics projects revenue between $530-552 million, representing 20-25% growth. The company maintained a strong cash position of $336.7 million as of December 31, 2024.